Biotech Stocks
“MAIA is one of the pioneers in telomere-targeted therapeutic strategies and is excited by the FDA’s approval of imetelstat for a rare blood cancer of bone marrow origin. We have found that telomere-targeted therapeutics as a mechanism of action can play an important role in treating certain cancers and we are investigating this science in our Phase 2 study of THIO in high-risk non-small cell lung cancer (NSCLC),” said Vlad Vitoc, M.D., Ph.D., Chairman and CEO of MAIA.
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA), a pioneer in telomere-targeted therapies, is harnessing the tremendous potential of telomere function to usher in a new era of cancer treatment. This novel approach received significant support with the recent FDA approval of imetelstat for hematologic malignancies, establishing a precedent that MAIA aims to follow in the fight against non-small cell lung cancer (NSCLC) with its lead candidate, THIO.
Innovative approaches to target cancer
Telomere targeting, a strategy pioneered by MAIA, plays a key role in treating certain cancers by disrupting the protective ends of chromosomes called telomeres, which are essential for cancer cell survival and proliferation. MAIA’s lead investigational drug, THIO (6-thio-2′-deoxyguanosine), exploits this vulnerability by integrating into cancer cell telomeres, causing rapid cell death.
Dr. Vlad Vitoc, Chairman and CEO of MAIA, highlighted the recent encouraging results from a Phase 2 study of THIO in patients with high-risk NSCLC resistant to checkpoint inhibitors and chemotherapy. “Our latest clinical data demonstrates the exceptional efficacy of THIO in these patients, and we commend Geron for validating this pathway,” said Dr. Vitoc.
THIO: A catalyst for change in non-small cell lung cancer treatment
THIO is more than just an anti-cancer drug. It is a telomere-targeted drug that induces a profound biological response in cancer cells. It not only damages telomeric DNA and directly kills cancer cells, but also triggers both innate and adaptive immune responses. This dual action makes THIO a strong candidate for sequential treatment with PD-(L)1 inhibitors, which have shown the potential to create cancer-specific immune memory and thereby induce significant and durable tumor regression.
Phase 2 Clinical Trial: THIO-101
The ongoing THIO-101 trial is a pioneering study designed to test the efficacy of THIO as an anti-cancer compound and priming immune activator. When administered at low doses prior to cemiplimab (Libtayo registered), it is hypothesized that THIO will enhance and sustain immune responses in patients with advanced NSCLC who have progressed after first-line treatment with other checkpoint inhibitors. “The aim of this trial is to evaluate the safety and tolerability of THIO and assess its clinical efficacy using overall response rate as the primary endpoint,” explained Dr. Vitoc.
Recent company highlights and major achievements
*
New Science in Cancer Care Drives Compelling Value Proposition
*
Lead drug THIO shows excellent efficacy in Phase 2 clinical trial
*
The company has raised over $12 million in funding so far this year, including $7.4 million in Q2 2024.
*
Ensuring continued insider investment through independent director participation in private equity financing
*
Latest data shows THIO demonstrates superior efficacy against standard treatments for non-small cell lung cancer (NSCLC)
*
The overall response rate (ORR) in the third-line (3L) setting (THIO 180 mg) is 38%, compared with approximately 6% for currently available therapies in a similar population.
*
The median progression-free survival (PFS) was 5.5 months (3L, THIO 180 mg), more than double the PFS of current chemotherapy.
I’m looking forward to
As MAIA Biotechnology continues to develop THIO and pursue its full potential, the oncology community watches in anticipation of a new and effective weapon against hard-to-treat cancers. With ongoing trials and a commitment to innovative cancer solutions, MAIA aims to not only participate in the evolution of cancer treatment, but to lead it. In this blog post, we leverage information directly relevant to MAIA Biotechnology’s advancement of telomere-targeted therapy, outline the clinical and regulatory path, and offer hope for the future of cancer treatment.
Other biotech stocks to watch include MIRA Pharmaceuticals (NASDAQ: MIRA), Cassava Sciences Inc (NASDAQ: SAVA), Incyte Corp (NASDAQ: INCY) and Jazz Pharmaceuticals (NASDAQ: JAZZ).
Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or a recommendation of MAIA or its strategies. It is for educational and informational purposes only and is not investment advice. Please read and understand the disclaimer in full at https://digitalcoinstandard.com//disclaimer/. https://digitalcoinstandard.com/ has received compensation of $500 from a third party, Momentum Media LLC, for content delivery services for MAIA on July 22, 2024. https://digitalcoinstandard.com/ is not an investment advisor or a registered broker. None of the current owners, employees, or independent contractors of https://digitalcoinstandard.com/ are registered as securities broker-dealers, brokers, investment advisors, or IA representatives with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements often contain words such as “believe,” “anticipate,” “estimate,” “expect,” “project,” “intend” and similar expressions regarding future performance or actions and are based on current expectations, estimates, and projections and are not historical facts. They involve various risks and uncertainties that could cause results or events to deviate materially from those anticipated. Past performance is not a guarantee of future results. https://digitalcoinstandard.com/ does not undertake to update forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in any transaction. https://digitalcoinstandard.com/ is not managed by a licensed broker, dealer, or registered investment advisor. The content here is purely for informational purposes and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor regarding forward-looking statements. Any statements that predict, forecast, expect, anticipate, estimate, believe or understand that certain actions may occur may be forward-looking statements and not historical facts. These statements are based on expectations, estimates and projections that actual results may differ materially from those anticipated. Investing in microcap and growth securities is speculative and involves a high degree of risk and may result in a total or substantial loss of your investment. Please note that the content published here does not constitute a recommendation to buy or sell securities. It is for informational purposes only and should not be construed as legal, tax, investment, financial or other advice. The content of this article does not constitute an offer or solicitation by https://digitalcoinstandard.com/ or any third party service provider to buy or sell securities or other financial instruments. The content of this article does not address the circumstances of any specific person or entity and does not constitute professional and/or financial advice. https://digitalcoinstandard.com/ is not a fiduciary with respect to the use of or access to this content.
Source: https://finance.yahoo.com/news/maia-biotechnology-announces-date-achievements-140700794.html
https://finance.yahoo.com/news/maia-biotechnologys-telomere-targeting-functionity-163100746.html
Media Contact
Company Name: DigitalCoinStandard
Contact: Ash K
Email: Send an email [https://www.abnewswire.com/email_contact_us.php?pr=maia-biotechnology-maia-is-one-of-the-earliest-pioneers-of-telomere-targeting-as-a-therapeutic-strategy]
Country: United States
Website: https://digitalcoinstandard.com/
This release was published on openPR.
